12:00 AM
 | 
Apr 19, 2002
 |  BC Extra  |  Company News

MedImmune in-licenses 2 cancer technologies

MEDI received exclusive worldwide rights to two cancer technologies: Human Aspartyl (Asparaginyl) Beta-Hydroxylase (HAAH) enzyme targeting technology from Panacea (Rockville, Md.) and technology targeting...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >